Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Immunogenicity of JHL1149 vs Bevacizumab in Healthy Male Volunteers
NCT03576651Phase 1Completed
- Sponsor
- Eden Biologics, Inc.
- Start
- Mar 2018
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JHL1149 in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), ovarian cancer and 3 more (3 arms), sponsored by Eden Biologics, Inc. Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Infinity up to 71 days. Started Mar 2018; status: completed.
02
Drugs
JHL1149
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)ovarian cancerCervical Cancer (CC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03576651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576651.